Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

SIMPLE SUMMARY: Since its recognition in 2016 as a distinct entity among acute myeloid leukemia (AML), no consensus on treatment has been established for managing blastic dendritic cell neoplasm (BPDCN). Patients seem sensitive to standard chemotherapies, but relapses and resistance development ofte...

Descripción completa

Detalles Bibliográficos
Autores principales: Poussard, Margaux, Angelot-Delettre, Fanny, Deconinck, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367503/
https://www.ncbi.nlm.nih.gov/pubmed/35954431
http://dx.doi.org/10.3390/cancers14153767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367503/
https://www.ncbi.nlm.nih.gov/pubmed/35954431
http://dx.doi.org/10.3390/cancers14153767

Ejemplares similares